A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults

Oncologist

Volumn 16, Issue 2, 2011, Pages 207-216

  Likun, Zhou ^a   Xiang, Jing ^a   Yi, Ba ^a   Xin, Duan ^b   Tao, Zheng Liu ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c University of Traditional Chinese Medical   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CONSTIPATION; DEXAMETHASONE; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; NAUSEA; NEOPLASMS; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 79952614719     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0198     Document Type: Article

References (43)

1. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331-340.
2. Osoba D, Zee B, Warr D et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and SymptomControl Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-313.
3. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-949.
4. Coates A, Abraham S, Kaye SB et al. On the receiving end: patient percep tion of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology-Antiemesis-v. 4. 2009. Available at: http://www.nccn.org, accessed March 2010.
6. Gralla RJ, Tyson LB, Kris MG et al. The management of chemotherapyinduced nausea and vomiting. Med Clin North Am 1987;71:289-301.
7. Hasler WL. Serotonin receptor physiology: relation to emesis. Dig Dis Sci 1999; 44(8 suppl):108S-113S.
8. Chevallier B, Marty M, Paillarse JM. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group. Br J Cancer 1994;70:1171-1175.
9. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy forcancer. N Engl J Med 1995;332:1-5.
10. Kleisbauer JP, Garcia-Giron C, Antimi M et al. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 1998;9:387-392.
11. Garcia-del-Muro X, Vadell C, Perez Manga G et al. Randomised doubleblind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer 1998;34:193-195.
12. Janinis J, Giannakakis T, Athanasiades A et al. A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study. Tumori 2000; 86:37-41.
13. Fauser AA, Pizzocaro G, Schueller J et al. Adouble-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatinrelated nausea and vomiting. Support Care Cancer 2000;8:49-54.
14. Villalon A, Chan V. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer 2004;12:58-63.
15. Gebbia V, Testa A, Valenza R et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer 1995;76:1821-1828.
16. Jordan K, Hinke A, Grothey A et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy induced emesis. Support Care Cancer 2007;15:1023-1033.
17. Herrstedt J, Roila F; ESMO Guidelines Working Group. Chemotherapyinduced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2008;19(suppl 2):2 110-112.
18. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43.
19. American Society of Clinical Oncology, Kris MG, Hesketh PJ et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. 2006;24:2932-2947.
20. Jordan K, Hinke A, Grothey A et al. Meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15:1023-1033.
21. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006;2:591-602.
22. Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008;107:469-478.
23. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer 2003;98: 2473-2482.
24. Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
25. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005;3:369-374.
26. Liu P, Feng FY, Wang SJ et al. Clinical research of palonosetron hydrochloride injection for prevention chemotherapy-induced nausea and vomiting [abstract]. Medical Frontier Forum and the Tenth National Conference on Cancer Pharmacology and Chemotherapy, Tsingtao, June 16-20, 2007.
27. R. Kadota, V. Shen Y. Messinger. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, doubleblind, phase 3, randomized study. J Clin Oncol 2007;25(suppl 18):9570.
28. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapyinduced nausea and vomiting in children. Arch Med Res 2008;39:601-606.
29. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-2087.
30. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.
31. Cheng YX, Qin SK, Cheng Y et al. A multicenter double-blind, randomized control clinical trial of palonosetron hydrochloride injection to prevent chemotherapy-induced nausea and vomiting. Chin Clin Oncol 2007;12:161-165.
32. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-124.
33. Yu ZC, Liu WC, Wang L et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 2009;17:99-102.
34. Li ZQ, Xu JM, Liu DQ et al. Phase II trial of hydrochloride in prevention of moderately to severely emetogenic chemotherapy induced nausea and vomiting. Chin Clin Oncol 2009;14:487-490.
35. Tian W, Wang Z, Zhou J et al. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Med Oncol 2010 Jan 5 [Epub ahead of print].
36. Aapro M, Fabi A, Nolé F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:1083-1088.
37. Li Q, Roddy JVF, Berger M. Palonosetron hydrochloride in the treatment of chemotherapy-induced nausea and vomiting. Clin Med: Ther 2009;1: 1145-1158.
38. Eisenberg P, MacKintosh FR, Ritch P et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330-337.
39. Gore S, Gilmore IT, Haigh CG et al. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990;4:139-144.
40. Scolapio JS, Camilleri M, von der OheMRet al. Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol 1995;30:562-567.
41. Lorusso V, Spedicato A, Petrucelli L et al. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Support Care Cancer 2009;17:1469-1473.
42. Kuo B, Camilleri M, Burton D et al. Effects of 5-HT (3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002;16:225-233.
43. Nielsen OH, Hvid-Jacobsen K, Lund P et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990;46:89-96.